Vector-borne diseases (VBDs), transmitted by vectors such as mosquitoes, ticks, and fleas, are a significant public health concern in India. This article provides a comprehensive analysis of the prevalence and management of VBDs in India, aimed at guiding healthcare professionals in their practice.
India's tropical climate and high population density make it a hotspot for VBDs. Malaria, dengue, and chikungunya are the most prevalent, with malaria accounting for approximately 88% of the Southeast Asia region's cases. Dengue cases have also escalated, with an estimated 100-200 million infections annually. The prevalence of Chikungunya has fluctuated in recent years, but outbreaks continue to occur.
Managing VBDs in India is challenging due to factors like inadequate healthcare infrastructure, lack of public awareness, and climate change. Additionally, the high cost of treatment and diagnosis, coupled with the absence of specific antiviral drugs for diseases like dengue and chikungunya, complicates the situation further.
Strategies to control VBDs in India include vector control, disease surveillance, and community participation. Vector control includes measures like insecticide-treated nets and indoor residual spraying. Disease surveillance involves monitoring and reporting cases to identify outbreaks early. Community participation is crucial for the success of these interventions, emphasizing the importance of health education.
Healthcare professionals play a pivotal role in managing VBDs. They are responsible for early diagnosis, appropriate treatment, and patient education. Furthermore, they can contribute to research, policy-making, and implementation of control strategies.
Vector-borne diseases pose a significant health burden in India. Effective management requires concerted efforts from healthcare professionals, policymakers, and the community. By understanding the prevalence and unique challenges presented by these diseases, professionals can contribute to their control and prevention.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation